GLP-1 maintenance dose protocols by drug 2026

TLDR. Each GLP-1 has a different maximum approved maintenance dose and a different clinical pattern at maintenance. Wegovy maintenance is 2.4 mg weekly for obesity. Zepbound maintenance is 5, 10, or 15 mg weekly, individualized. Ozempic maintenance is 1 or 2 mg weekly for T2D. Mounjaro maintenance is 5 to 15 mg weekly for T2D. Maintenance is not the same as the highest tolerated dose; it is the lowest dose that preserves the clinical goal. STEP-4 and SURMOUNT-4 confirm continued therapy is required to maintain weight loss. Stopping produces predictable regain. Tapering is appropriate only in specific clinical scenarios.

Patients reach maintenance dose between week 16 and week 24 of GLP-1 therapy, depending on the molecule and the titration schedule. The maintenance dose is the dose the patient stays on indefinitely once active weight loss has plateaued or the clinical goal has been reached.

The word "maintenance" is doing a lot of work. Maintenance is the lowest dose that preserves the clinical effect, not necessarily the highest tolerated dose. The patient who lost 30 percent body weight on Zepbound 15 mg may maintain that loss on Zepbound 10 mg or even 7.5 mg, freeing dose headroom for future use and potentially reducing side effects. The patient who has lost 14 percent on Wegovy 2.4 mg may need to stay at 2.4 mg to preserve the loss.

This post lays out the approved maintenance doses for each drug, what the trial data says about reducing the dose after weight stabilization, and the specific clinical scenarios where tapering or stopping is appropriate.

Wegovy maintenance protocol

The FDA-approved Wegovy maintenance dose for obesity is 2.4 mg weekly. The standard titration:

• Weeks 1 to 4: 0.25 mg
• Weeks 5 to 8: 0.5 mg
• Weeks 9 to 12: 1.0 mg
• Weeks 13 to 16: 1.7 mg
• Weeks 17 onward: 2.4 mg (maintenance)

The label permits a reduced maintenance dose of 1.7 mg weekly if the patient cannot tolerate 2.4 mg. Below 1.7 mg, the obesity label does not support continued use; patients who cannot tolerate 1.7 mg typically discontinue Wegovy or switch molecule.

For the cardiovascular indication, the Wegovy 2.4 mg dose is the labeled dose for major adverse cardiovascular event reduction in patients with established CVD and BMI 27 or higher. Reducing below 2.4 mg has not been studied for CV outcomes.

Zepbound maintenance protocol

Zepbound has the most flexible maintenance protocol of the GLP-1 class. The FDA label specifies 5 mg, 10 mg, or 15 mg weekly as approved maintenance doses, individualized to patient response and tolerance.

The standard titration:

• Weeks 1 to 4: 2.5 mg
• Weeks 5 to 8: 5 mg
• Maintenance choice: continue at 5 mg, or escalate every 4 weeks to 7.5 mg, 10 mg, 12.5 mg, 15 mg

The flexibility means individual patients land at different maintenance doses based on response. A patient achieving target weight at 5 mg stays at 5 mg. A patient needing additional loss escalates. The SURMOUNT-1 trial showed mean weight reduction of 15.0 percent at 5 mg, 19.5 percent at 10 mg, and 20.9 percent at 15 mg, demonstrating the dose-response curve.

For the OSA indication (SURMOUNT-OSA), maintenance is typically 10 to 15 mg weekly. For the HFpEF indication (SUMMIT), maintenance is typically 15 mg weekly.

Ozempic maintenance protocol

Ozempic is the T2D-labeled semaglutide product. The FDA-approved maintenance doses for T2D are 0.5 mg, 1 mg, or 2 mg weekly, individualized to glycemic response.

The standard titration:

• Weeks 1 to 4: 0.25 mg (non-therapeutic, for tolerance)
• Weeks 5 onward: 0.5 mg (initial therapeutic maintenance)
• If A1C goal not reached after at least 4 weeks at 0.5 mg: escalate to 1 mg
• If A1C goal not reached after at least 4 weeks at 1 mg: escalate to 2 mg

The 2 mg dose became available in 2022 after the SUSTAIN FORTE trial demonstrated additional A1C and weight reduction over 1 mg. Most T2D patients reach glycemic goal at 1 mg; the 2 mg dose is reserved for patients needing additional A1C reduction.

Ozempic is not FDA-approved for obesity. Off-label use of Ozempic for weight loss in patients without T2D is common; some prescribers titrate to 2 mg for the weight effect. This is not labeled use, and the Wegovy 2.4 mg dose was approved specifically because the 2 mg dose was insufficient for the obesity indication's efficacy bar in the STEP trials.

Mounjaro maintenance protocol

Mounjaro is the T2D-labeled tirzepatide product. The FDA-approved maintenance doses are 5 mg, 10 mg, or 15 mg weekly, individualized to glycemic response.

The standard titration:

• Weeks 1 to 4: 2.5 mg (non-therapeutic, for tolerance)
• Weeks 5 onward: 5 mg (initial therapeutic maintenance)
• If A1C goal not reached after at least 4 weeks at 5 mg: escalate every 4 weeks through 7.5 mg, 10 mg, 12.5 mg, 15 mg

Most T2D patients reach glycemic goal between 5 mg and 10 mg. The 15 mg dose is reserved for patients with inadequate A1C control at lower doses or for patients prioritizing weight reduction alongside glycemic control.

What "maintenance" actually means clinically

The maintenance phase is defined by three conditions:

1. The patient has reached the clinical goal (target weight, target A1C, or both).
2. The patient has stabilized at a dose level for at least 8 weeks without GI breakthrough.
3. The patient continues at the stable dose indefinitely to preserve the clinical effect.

Maintenance is not "the dose I am on now." It is the equilibrium between dose, clinical effect, and tolerance. Patients can be at maintenance for years. Patients can also re-enter active titration if clinical goals shift (a new weight target, a new comorbidity, a new dose-limiting side effect).

Why patients consider reducing the maintenance dose

Three reasons patients ask about reducing their dose:

• Side effect management. Patients who tolerated 15 mg during active titration sometimes find lingering low-grade GI symptoms at maintenance. A step down to 10 mg or 7.5 mg can ease the symptoms with limited weight regain.
• Cost reduction. Some cash-pay programs price lower doses cheaper. NovoCare Wegovy costs $349 for 0.25 to 0.5 mg and $499 for 1.0 mg and above, so titration steps and full maintenance both fall on the higher tier. LillyDirect Zepbound vials are similarly tiered ($349 for 2.5 to 5 mg, $499 for 7.5 mg and up). For Zepbound patients, dropping from 15 mg to 5 mg meaningfully reduces cash-pay cost.
• Long-term sustainability. Some patients prefer the lowest effective dose on principle, both for tolerance and for keeping dose headroom available if active weight loss is needed later.

What the trial data says about dose reduction in maintenance

The trials studied stopping the medication, not reducing it. STEP-4 (semaglutide) and SURMOUNT-4 (tirzepatide) both compared continuing maintenance dose to switching to placebo. The placebo arms regained weight predictably.

STEP-4: Patients who completed 20 weeks of titration to 2.4 mg semaglutide were randomized to continue 2.4 mg or switch to placebo for an additional 48 weeks. Continued therapy: -7.9 percent additional body weight. Placebo: +6.9 percent regain. Net difference: 14.8 percentage points.

SURMOUNT-4: Patients who completed 36 weeks of titration to maintenance tirzepatide were randomized to continue maintenance dose or switch to placebo for an additional 52 weeks. Continued therapy: -5.5 percent additional body weight. Placebo: +14 percent regain. Net difference: 19.5 percentage points.

Neither trial directly studied a maintenance-dose reduction (e.g., dropping from 15 mg to 5 mg). Clinical practice has filled the gap with reasonable but unprovable guidance: reducing the maintenance dose by one step at a time, with 8 to 12 weeks of observation at the lower dose before further reduction, is generally tolerable. If weight regain is more than 2 percent over 12 weeks at the reduced dose, return to the prior dose.

The taper question

Patients sometimes ask whether they can taper off the GLP-1 entirely after sustained weight loss. The trial data is unambiguous: stopping produces regain.

The 12-month regain pattern from STEP-4 and SURMOUNT-4:

• STEP-4 placebo arm regained 6.9 percent body weight over 48 weeks.
• SURMOUNT-4 placebo arm regained 14 percent body weight over 52 weeks.

The mechanism is the same metabolic adaptation that drives the plateau: the body's lower-weight equilibrium is not stable without continued appetite suppression. The patient is not "back to baseline" when they stop; they are at a body weight defended by physiology that is no longer being countered by the medication.

Tapering off GLP-1 therapy is appropriate in two specific scenarios:

1. Pregnancy planning. GLP-1s are not safe in pregnancy. Patients planning to conceive should taper off before conception, accept the likely regain, and revisit the medication after delivery and lactation. The Wegovy and Zepbound labels are explicit on this point.
2. Resolution of a precipitating condition. A patient who took Mounjaro for T2D and whose T2D resolved (sustained A1C below 6.5 with normal fasting glucose, no diabetes medications) may have a path to taper. Most patients who taper after T2D resolution will see A1C drift back up, but the trial data here is weaker and individual variation is large.

For pure weight management without one of these clinical scenarios, the evidence supports continued therapy at the lowest effective dose, not tapering.

The cost dimension of dose choice

For cash-pay patients, the dose chosen at maintenance directly affects monthly cost. For Wegovy, NovoCare direct prices 0.25 to 0.5 mg at $349 per month and 1.0 mg and above at $499 per month. A patient maintaining at 1.7 mg pays $499; a patient maintaining at 2.4 mg also pays $499; a patient titrating back down to 1.0 mg still pays $499. The cost cliff is between 0.5 mg and 1.0 mg.

For Zepbound vials through LillyDirect, the tiers are similar: $349 for 2.5 mg and 5 mg, $499 for 7.5 mg and above. A Zepbound patient maintaining at 5 mg pays $349; at 7.5 mg or higher, $499. The cost cliff is between 5 mg and 7.5 mg.

For insured patients, the cost is the copay tier, which is usually flat across doses. Dose choice does not affect copay.

The implication for cash-pay patients: if maintenance can be achieved at 0.5 mg semaglutide or 5 mg tirzepatide, the savings vs the higher-tier doses are roughly $150 per month, or $1,800 per year. This is real money for patients planning multi-year therapy.

Long-term maintenance: STEP-5 and beyond

The longest available trial data on GLP-1 maintenance is STEP-5, which followed patients on semaglutide 2.4 mg for 104 weeks (two years). Mean total body weight reduction at week 104: 15.2 percent, slightly better than the STEP-1 one-year result (14.9 percent), suggesting modest additional loss in year two and durable maintenance of the achieved loss.

Real-world maintenance data beyond two years is still being collected. The Lilly TRACK and Novo STEP-UP registries are following maintenance patients for five-plus years. Early signals suggest the maintenance pattern from years one to two extends through years three to five with continued medication. Weight regain on continued therapy is small (1 to 3 percent over years two to five) and is partially explained by the natural aging-related weight gain pattern.

The clinical message: GLP-1 maintenance therapy is a long-duration commitment, not a discrete weight-loss episode. Patients should plan financially and clinically for indefinite therapy unless one of the taper scenarios applies.

Frequently asked questions

What is the maintenance dose of Wegovy?

The FDA-approved maintenance dose of Wegovy for obesity is 2.4 mg weekly. The label permits a reduced maintenance dose of 1.7 mg weekly if 2.4 mg is not tolerated. Below 1.7 mg, the obesity label does not support continued use.

What is the maintenance dose of Zepbound?

Zepbound has three FDA-approved maintenance doses: 5 mg, 10 mg, or 15 mg weekly, individualized to patient response. Most patients land at 10 or 15 mg for maximum weight effect; patients who reach target weight at 5 mg can stay there.

Can I stay on the lower titration doses indefinitely?

For Wegovy, no, the obesity label only supports 1.7 mg or 2.4 mg as maintenance. For Zepbound, yes, the label supports 5 mg as a maintenance dose. For Ozempic, yes, 0.5 mg is a valid T2D maintenance dose for patients at glycemic goal. For Mounjaro, yes, 5 mg is a valid maintenance dose.

Will I regain weight if I stop my GLP-1?

Almost certainly. STEP-4 showed 6.9 percent body weight regain over 48 weeks after stopping semaglutide. SURMOUNT-4 showed 14 percent regain over 52 weeks after stopping tirzepatide. The mechanism is metabolic adaptation; the body defends a higher weight set-point when the medication's appetite suppression is removed.

Can I reduce my maintenance dose to save money?

For Zepbound and Mounjaro, yes, with caution. Drop one dose step (e.g., 15 mg to 10 mg), observe for 8 to 12 weeks, and return to the prior dose if weight regain exceeds 2 percent. For Wegovy, the only reduction option is 1.7 mg, which preserves most of the 2.4 mg effect for many patients but is not supported by long-duration trial data. For Ozempic, dropping from 2 mg to 1 mg is a labeled option if A1C remains at goal.

What is the lowest maintenance dose for weight loss?

For Wegovy: 1.7 mg weekly is the lowest labeled obesity maintenance dose. For Zepbound: 5 mg weekly. Patients using Ozempic off-label for weight management often maintain at 1 mg weekly, but this is not labeled use.

How long can I stay on the maximum dose?

Indefinitely, per current label and trial data. STEP-5 followed semaglutide 2.4 mg for 104 weeks without dose modification. SURMOUNT trials follow tirzepatide 15 mg without label-mandated reduction. Real-world registries are following maintenance patients for 5-plus years without dose ceiling. The clinical question is whether the patient still needs the maximum dose; tolerance and continued goal achievement guide individual choice.

What happens to body composition during maintenance?

Lean mass loss during active weight loss is roughly 20 to 30 percent of total mass lost. During maintenance, body composition tends to stabilize: lean mass loss slows substantially, and fat mass remains the dominant component of any further loss. Resistance training and adequate protein intake (1.2 to 1.6 g per kg body weight) during both active loss and maintenance reduces the lean-mass loss component.

Does maintenance dose differ if I have type 2 diabetes vs obesity?

Yes. Wegovy and Zepbound (obesity labels) define maintenance at the doses needed for sustained weight management. Ozempic and Mounjaro (T2D labels) define maintenance at the doses needed for A1C control. Patients with both conditions often land at a dose that addresses both, but the labeled maintenance protocol differs by indication and the patient should know which label their prescription falls under.

Citations

• FDA. Wegovy (semaglutide) prescribing information, dosing and administration. accessdata.fda.gov/drugsatfda_docs/label/2024/215256s011lbl.pdf
• FDA. Zepbound (tirzepatide) prescribing information, dosing and administration. accessdata.fda.gov/drugsatfda_docs/label/2024/217806s006lbl.pdf
• FDA. Ozempic (semaglutide) prescribing information, dosing and administration. accessdata.fda.gov/drugsatfda_docs/label/2022/209637s020lbl.pdf
• FDA. Mounjaro (tirzepatide) prescribing information, dosing and administration. accessdata.fda.gov/drugsatfda_docs/label/2024/215866s016lbl.pdf
• Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP-4). JAMA 2021;325:1414-1425. jamanetwork.com/journals/jama/fullarticle/2777886
• Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4). JAMA 2024;331:38-48. jamanetwork.com/journals/jama/fullarticle/2812936
• Garvey WT, et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP-5). Nat Med 2022;28:2083-2091. nature.com/articles/s41591-022-02026-4
• American Diabetes Association. Standards of Care in Diabetes 2026. diabetesjournals.org/care/issue/49/Supplement_1